Amgen presents late-breaking Phase 2 olpasiran data at ESC 2023

Amgen today announced data from the final analysis of the Phase 2 OCEAN(a)-DOSE study of olpasiran, a small interfering RNA (siRNA) during the Late-Breaking Science Session at the European Society of Cardiology (ESC) Annual Meeting being held in Amsterdam. In the off-treatment extension period, olpasiran showed a lasting effect on Lp(a) reduction nearly a year after the last dose.

MHRA approves licence change for Pfizer-BioNTech’s vaccine

Share this article The formulation of the Comirnaty vaccine, approved in September 2023, remains unchanged. Credit: Studio Romantic / Shutterstock.com. The UK Medicines and Healthcare

February 12, 2024

Opioid-Free Discharge After Pancreatic Resection Can Be Achieved, Study Shows

Inpatient oral morphine equivalents (OMEs) were halved and median discharge OMEs were reduced to zero for pancreatic resection patients at a single center after two

September 7, 2023

Meta Title: Allscripts Healthcare Solutions Inc Patent Filing for Medical Software Optimization

Share this article According to GlobalData’s company profile on Allscripts Healthcare Solutions, was a key innovation area identified from patents. Allscripts Healthcare Solutions’s grant share

April 15, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.